Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersNeurology Physician in Statesville, NC
NPI: 1437441052Primary Practice Location
Piedmont Healthcare, PA
208 Old Mocksville Rd, Statesville, NC
Primary Employer
Piedmont Healthcare, P.A.
piedmonthealthcare.com
HQ Phone
Get M.D. Matthew's Phone NumberMobile
Get M.D. Matthew's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
NC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 85 | 124 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 67 | 111 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 54 | 79 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 47 | 47 |
| 5 | 96413Infusion of chemotherapy into a vein up to 1 hour | 15 | 29 |
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Authors: Ann Bass, Regina Berkovich, Brian Steingo, Gabriel Pardo, Carolina Ionete
Publication Date: 2020-06-24
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
Authors: Ontaneda, Daniel, Nicholas, Jacqueline, Carraro, Matthew, Zhou, Jia, Hou, Qiang, Babb, Jaanai, Riester, Katherine, Mendoza, Jason P, Livingston, Terrie, Jhaveri, Mehul
Journal: Mult Scler Relat Disord
Publication Date: 2018-10-10
Lead Sponsor: Johns Hopkins University
Collaborators: Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Intervention / Treatment: OTHER: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, OTHER: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
Lead Sponsor: Genzyme, a Sanofi Company
Collaborators: Bayer
Intervention / Treatment: BIOLOGICAL: Interferon beta-1a, BIOLOGICAL: Alemtuzumab 12 mg, BIOLOGICAL: Alemtuzumab 24 mg
Lead Sponsor: Genzyme, a Sanofi Company
Intervention / Treatment: DRUG: alemtuzumab GZ402673
